Press Releases
Back to Previous Page
 


News Release

August 19, 2019
Your Contact:
karen.tiano@milliporesigma.com
Phone: +1 978 495 0093


MilliporeSigma Granted 20 CRISPR Patents Total Worldwide

  • Patent offices in Europe, Israel, South Korea and U.K. issue seven additional grants for MilliporeSigma’s CRISPR genome-editing technology
  • MilliporeSigma has 20 allowed CRISPR patents to date across nine different geographies

Burlington, Massachusetts, August 19, 2019 — MilliporeSigma, a leader in genome editing, today announced that the European, Israeli, South Korean and U.K. intellectual property offices have issued formal notices allowing MilliporeSigma’s patent application claims covering CRISPR gene-editing technology, bringing the number of patents to 20 worldwide.

“It is encouraging to see this important body of scientific work recognized with the grants of these latest CRISPR patents,” said Udit Batra, CEO, MilliporeSigma. “Our ambition is to continue growing our CRISPR intellectual property portfolio with technologies such as paired Cas9 nickases, for reducing off-target effects, and proxy-CRISPR, which offers researchers more experimental options to accelerate drug development and access to new therapies.”

Details on MilliporeSigma’s latest patent awards are as follows:

  • European Patent Office — Patent allowances for:
    • Vectors for CRISPR integration. The newly allowed claims cover vector compositions to support CRISPR delivery and expression in eukaryotic cells, including viral delivery methods broadly used in both cancer research (lentivirus) and human therapeutic applications (adeno-associated virus, or AAV).
    • proxy-CRISPR technology, which provides access to modify difficult-to-reach genomic regions, expanding CRISPR design options. This approach also allows a reduction in off-target effects.
    • Engineered Ribonucleic Acid (RNA)-guided endonuclease and protein- RNA complexes.
      (These two newly allowed claim sets cover compositions that can be used for gene knock-in and gene knockout.)
  • Israeli IP Office — Patent allowance for:
    • Paired Nickase technology, to reduce off-target effects. Paired nickases represent a significant step in increasing genome-editing safety.
  • South Korean IP Office — Patent allowance for:
    • Paired Nickase technology.
  • U.K. (IP) Office — Patent allowance for:
    • proxy-CRISPR technology.

In addition to Europe, Israel, U.K. and South Korea, MilliporeSigma has CRISPR-related patents in the following regions: U.S., Canada, Australia, China and Singapore. It was awarded its first foundational patent in Australia covering CRISPR integration in 2017, and its first U.S. CRISPR patent for proxy-CRISPR in 2019.

Earlier, MilliporeSigma announced different CRISPR patents in Europe in 2017 and in South Korea and Israel in 2018.

On July 18, 2019, MilliporeSigma announced a CRISPR licensing framework with Broad Institute of MIT and Harvard to offer non-exclusive licenses to CRISPR IP under their respective control for use in commercial research and product development. This new framework aims to simplify and accelerate scientific access to CRISPR IP.

On July 19, 2019, MilliporeSigma filed a petition with the U.S. Patent and Trademark Office requesting an interference proceeding between CRISPR-Cas9 patents the company applied for in 2012 and patents that UC Berkeley has applied for or been awarded.

The company has been at the forefront of innovation in the field for 15 years, with experience spanning from discovery to manufacturing.

MilliporeSigma supports research with genome editing under careful consideration of ethical and legal standards. Its parent company, Merck KGaA, Darmstadt, Germany, has established an independent, external Bioethics Advisory Panel to provide guidance for research in which its businesses are involved, including research on or using genome editing, and has defined a clear operational position taking into account scientific and societal issues to inform promising therapeutic approaches for use in research and applications.

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

About the Life Science Business of Merck KGaA, Darmstadt, Germany

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 21,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Udit Batra is the global chief executive officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 56,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of €14.8 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.